Established October 2019
Pharmacoepidemiologic studies are essential to confirm (or refute) and elucidate the health effects of potential drug-drug interactions (DDIs). In addition to applying principles for good pharmacoepidemiology practice, researchers conducting DDI studies must consider nuances in design and interpretation that follow from a focus on the health effects of combinations of multiple exposures rather than single medical products. The DDI Special Interest Group will serve as a collaborative community of ISPE members with an interest in the design, analysis, interpretation, and translation of pharmacoepidemiologic studies of drug interactions.
Please visit our ISPE Community for the latest SIG news, upcoming meetings, membership, documents library, connecting with SIG members and leaders, and more. An account is needed to access the community and join it.
|Chair||Charles Leonard, US|
|Vice Chair||Katsiaryna Bykov, US|
|Secretary||Thanh Phuong Pham Nguyen, US|